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Abstract 
The Argonaute proteins constitute a highly conserved family of nucleic acid-binding proteins whose members have 
been implicated in RNA interference (RNAi) and related phenomena in several organisms. In particular, Argonaute 2 
(Ago2) represents one of the key players in the RNA induced silencing complex (RISC). However, recently published 
literature describes that Ago2 itself is regulated under certain cellular conditions by post-translational modifications. In 
this work, we investigated the activity of human Ago2 under various conditions of cell stress. Under such conditions, 
the sub-cellular localization of Ago2 was altered which was coincident with its decreased function in the RNAi 
pathway. This work implies that specific cellular stress conditions induce an intracellular translocation of Ago2 protein 
excluding it from sites of action of the RNAi machinery. Details will be presented and discussed. 
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Abstract 
Although microRNAs (miRNAs) have been shown to regulate genes that play roles in important biological processes 
such as development, differentiation and disease, identifying miRNAs of interest and characterizing their mechanism of 
action remains a challenge.  The miR-200 family has been shown to regulate epithelial to mesenchymal transitions 
(EMT), a process that is critical for normal development and tumor metastasis.  Furthermore, recent publications 
indicate that the miR-200 family regulates EMT by targeting ZEB1 and ZEB2, transcription factors that repress E-
cadherin. Here, we use breast cancer cell lines as an EMT model system to characterize the miR-200 family’s role in 
these biological processes.   miRIDIAN microRNA microarray profiling was use to characterize cell lines followed by 
introduction of miRIDIAN miRNA mimics and hairpin inhibitors to modulate miRNA expression in these cell lines.  
Based on these studies we have devised a workflow for studying miRNA expression and identifying miRNA targets. 368 
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Abstract 
Small interfering RNAs (siRNAs) are promising new active compounds in gene medicine. But one serious problem 
with delivering siRNAs as treatment is the well-established stimulation of innate immune reactions by some RNA 
duplexes and lack of effective delivery systems. Innate immune  reactions towards double stranded RNAs include the 
2´-5 oligoadenylate (OAS) system, the protein kinase R (PKR), RIG-I and Toll-like receptor activated pathways all 
resulting in activation of antiviral defence mechanism. We have previously described a high throughput animal 
screening model in which the level of stimulation of interferon-related anti viral effects is measured as increased 
resistance of siRNA-injected small fish to a pathogenic virus. Here we show how this fish model can be used to make a 
fast in vivo analysis of the effect of chemical base modification in the siRNAs on the level of antiviral off-target effects. 
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Abstract 
Defects in DNA repair and damage response can drive tumour progression and results in genomic instability in tumour 
cells. Whereas these DNA repair defects can be exploited in cancer therapy where unrepaired lesions induced by anti-
cancer agents increase tumour killing, these DNA repair defects can also cause resistance to anti-cancer treatments. 
Defects in DNA repair pathways may also render tumour cells dependent on other complementary repair pathways as 
seen with the synthetic lethal effect of PARP inhibitors in BRCA-defective tumours. Altogether, there is a potential use 
of DNA repair inhibitors in anti-cancer treatment, either in combination therapy to increase the efficacy of e.g. radiation 
or as mono-therapy to target essential compensatory DNA repair pathways. Homologous recombination (HR) is a repair 
pathway involved in repairing double-strand breaks and replication-associated lesions, the main toxic lesions induces by 
anti-cancer drugs. Depletion of the key protein involved in HR, the RAD51 protein, is lethal but loss of other proteins 
involved in HR is compatible with survival. To understand the wider network of HR proteins and with the aim to find 
novel proteins that can be used as targets for HR-inhibition, we have used a RNAi screen approach to create functional 
genetic network maps describing proteins involved in homologous recombination. Foci formation of the RAD51 protein 
has been studied in U2OS cells subjected to protein knock-down using a RNAi library in co-treatment with either 
irradiation or camptothecin. This identifies proteins involved in the HR response to different types of lesions. In 
addition, a GFP-reporter-based HR assay has been used to identify proteins involved in HR repair of a site-specific 
double-strand break. With these experiments we hope to increase our understanding of the complex network of 
homologous recombinational repair as well as find potential targets for anti-cancer treatments. 
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Abstract 
The canonical Wnt/β-Catenin pathway controls myriad fundamental cellular processes, such as differentiation and 
proliferation.  Aberrant regulation of this signaling cascade can result in several disease phenotypes and is a hallmark of 
colorectal cancer and hepatocellular carcinoma.  Genetic evidence links Wnt/β-Catenin signaling to the control of bone 
density.  The identification of new components of this pathway may lead to the development of novel therapies 
targeting a variety of cancers and osteoporosis.  Accordingly, we have conducted genome scale RNAi screens in 
multiple cell contexts to discover new pathway regulators.  We developed a screening process that included steps for 
initial hit identification, mitigation of off target effects, elimination of cell line-specific effects, and measurement of 
Wnt/β-Catenin signature regulation.  We further validated a number of these new pathway mediators in vitro for 
physical association with canonical pathway members and in vivo by use of zebrafish models.  These studies have 
characterized AGGF1, BTK, and DHFR as new modulators or the Wnt/β-Catenin pathway. 
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Abstract 
SiRNA molecules have a high potential for therapeutic applications. Here we present a mechanism of cell-specific, 
peptide-blocked siRNA. SiRNA is bound to short peptides preventing RISC formation. Peptides contain target 
sequence of peptidases, exclusively active in target cells. After intracellular delivery, only in target cells, peptidases 
cleave peptides leading to siRNA activation. Used peptide sequence is the target sequence for caspase-4, expressed 
in Jeg-3 choriocarcinoma and MCF-7 mammalian cancer cells, but not in human embryonic kidney (HEK) cells. We 
aimed to silence Signal Transducer of Activation (STAT3) expression by such modified siRNA specifically in Jeg-3 
as well as MCF-7 in contrast to HEK cells. Western blot was performed to detect STAT3 protein. Furthermore, 
proliferation of STAT3 silenced cells was analysed. The peptide was bound to the siRNA antisense strand via amino-
C6-linker based on Fmoc chemistry. Correct binding was analysed by PAGE and Maldi-MS. In Jeg-3 and MCF-7 
modified siRNA became activated and reduced STAT3 expression in contrast to HEK cells lacking caspase-4. 
Moreover, proliferation was significantly reduced in STAT3 silenced cells. In conclusion, STAT3, which is 
responsible for increased proliferation and invasive properties of various cancer cells, can be cell-specifically 
silenced using the presented novel technology. Preliminary experiments indicate that the presented mechanism of 
peptide-inhibited; peptidase-activated siRNA can be transferred to a variety of cell specific active peptidases and 
related disease models. 
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Abstract 
Background: RNA interference (RNAi), the degradation of cognate mRNA by small interfering RNA (siRNA), has 
emerged as a promising therapeutic entity for viral infections, including hepatitis C virus (HCV) HCV. In plants and 370 
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invertebrates, RNAi-mediated protection can spread to neighboring cells; however, such a phenomenon has not been 
described in mammalian cells.  In this study, we investigated whether endogenous expressed liver-specific 
microRNA and vector-delivered siRNA can transfer between cells and whether this exchange could extend the 
therapeutic effect of RNAi against HCV infection.  Methods: Human hepatoma cell lines Huh7 and HepG2, Huh7-
ET HCV replicon cells, and renal epithelial line 293T were co-cultured with conditioned medium or cells stably 
transduced with integrating lentiviral vectors expressing green fluorescent protein (GFP) and small hairpin RNAs 
targeting the HCV NS5b (LV-shNS5b), CD81 (LV-shCD81) or non-targeted control (LV-shCon). Liver-specific 
microRNA, miR-122, was quantified by real-time RT-PCR.  Results: MiR-122 is not only highly expressed in Huh7 
cells but also detectable in Huh7-CM, suggesting release of miR-122 by the cells. Upon incubation of HepG2 or 
293T cells, which are 200 and 50,000-fold lower in miR-122 expression, with Huh7-CM the miR-122 level in these 
cells was increased by 4-20 fold, indicating uptake of miR-122 from the medium. To further investigate whether 
small interfering RNA delivered by vectors can be transferred between cells, Huh7-ET was co-cultured with stably 
transfected Huh7 cells expressing shNS5b or shCon. A significant reduction of viral replication was observed at 1:1 
ratio of shNS5b cells (52±12% p<0.01) but not with shCon cells. Similarly, at suboptimal transduction of Huh7 with 
LV-shCD81, CD81 expression of non-transduced cells was also significantly down-regulated (30±12.9%, P<0.001). 
Moreover, conditioned medium of transduced cells could convey RNAi-mediated silencing of HCV (39%±12, 
P<0.01) and CD81 (23.5%±5.1, P<0.01) without transfer of GFP, suggesting a similar mechanism of transfer as for 
microRNA. Conclusion: It was shown that transmission of small RNA is an innate function of human cells which 
can both mediate the exchange of microRNA and vector delivered RNAi, thereby extending the therapeutic effects of 
RNAi on HCV. 
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Abstract 
Borane (–BH3) chemistry offers some unique chemical characteristics that make these compounds promising for 
enhancing the potential of three anticancer strategies; (a) RNA interference (siRNA) (b) the selection of tumor 
specific aptamers and (c) Boron Neutron Capture Therapy, a highly selective type of radiation therapy. Borane 
oligonucleotides are nuclease resistant and have increased lipophilicity compared to natural oligonucleotides, yet the 
modified borane nucleotide triphosphates (NTPαBs) still are efficiently recognized and utilized by RNA polymerase 
enzymes which enable the enzymatic synthesis of RNA (siRNA and aptamers). The novel properties of 
boranophosphate RNA molecules could lead to an increase in affinity and specificity of the siRNA and aptamers, as 
well impart stability of the nucleic acids to cellular nucleases. We hypothesize that borane-RNA molecules will 
interact a new diverse array of ligand sites in proteins (RISC siRNA carriers or ErbB2 therapeutic target) because of 
the distinct hydrophobicity, shape, and polarity properties imparted by the phosphorus-boron (P-B) chemical bond 
compared to the natural phosphorus-oxygen (P-O) bond. (a) A major cause of chemotherapeutic treatment failure 
against human cancers is the aberrant regulation of genes such as MDR1 in cancer cells.  Controlling the expression 
of cancer genes with antisense technology is a possible cancer therapy. MDR1 codes for a p-glycoprotein (Pgp) that 
is overexpressed in multidrug resistant cancer cells.  Specifically, using modified Small interfering RNAs (siRNAs) 
that target and degrade the p-glycoprotein mRNA produced by the MDR1 gene can be used to correct the 
overexpression of p-glycoprotein. (b) The selection of boranophosphate modified RNA aptamers by the SELEX 
(Systematic Evolution of Ligands by EXponential enrichment) against ErbB2.  It is likely that targeting a more 
specific cancer membrane target such as the ErbB2 receptor with a borane RNA aptamer may also be an effective 
two-prong strategy in breast cancer therapy.  Like the antibody protein, Herceptin, an aptamer may assume a distinct 
shape and block the receptor.  (c) Further, borane aptamers can be used as specific carriers of 10B in Boron Neutron 
Capture Therapy (BNCT). BNCT specifically destroys tumor cells near boron molecules. The selection of α-P-
borano-modified RNA aptamers against receptors highly over-expressed in breast cancer should provide the 
opportunity of testing the efficacy of a target specific method for delivering boron to the cancer cells. Such boron 
molecules could be potent and unique anti-tumor surrogates for antibodies because of their ease in selection, smaller 
size, nuclease resistance, susceptibility to BNCT, and versatility in terms of adding chemical modifications to 
increase potency. 371 
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Abstract 
The RNA silencing pathway is engaged during the cellular innate immune response to double-stranded RNA. Particularly 
in plants, this serves as an anti-viral defense mechanism and results in the degradation of homologous viral RNA. Several 
viruses have evolved mechanisms to undermine the RNA silencing pathway. Tombusviruses, such as the Carnation Italian 
Ringspot virus (CIRV), express a 19 kDa protein (p19) which acts as a suppressor of the RNA-silencing pathway. As a 
dimer, p19 binds double stranded small RNAs in a size-selective and relatively sequence-independent manner, thereby 
preventing their incorporation into RISC. The p19 protein binds 21 nucleotide double-stranded small RNAs with 
nanomolar affinity. These unique selective binding features allow p19 to be used as a molecular ruler that can be used to 
detect small RNAs. We have further increased the potential of the p19 protein through engineering several recombinant 
p19 proteins which allow us to detect protein-RNA interactions in solution. By constructing linked versions of the CIRV-
p19 dimer we have improved the stability and binding affinity of the p19 dimer while still maintaining its ability to 
discriminate RNA according to length. A recombinant p19-CFP fusion protein allows us to use fluorescence-based 
techniques to detect and quantify protein-RNA interactions based on Förster Resonance Energy Transfer (FRET). In this 
method, when the linked recombinant p19-CFP dimer binds Cy3-labelled dsRNA, intermolecular FRET occurs between 
the CFP donor and the Cy3 acceptor giving a quantifiable signal. In order to extend this methodology to in vivo detection 
of small RNA, we have developed an intramolecular FRET probe which incorporates YFP, another GFP analog, into the 
2x-p19-CFP recombinant protein. Progress towards using this ‘chameleon’ recombinant protein, CFP-2x-p19-YFP, as a 
FRET-based probe for live-cell imaging of small RNA production and localization will be presented. 
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Abstract 
RNA interference (RNAi) is a highly evolutionary conserved RNA-dependent gene silencing process initiated by short 
double-stranded RNA molecules. These include micro RNA and short interfering RNA (siRNA), the latter causing 
sequence-specific degradation of homologous mRNA sequences. Soon after the groundbreaking discovery of siRNA-
mediated regulation of gene expression, the RNA induced silencing complex (RISC) was found to be the effector complex 
of RNAi with argonaute proteins as the catalytic component. Here, HeLa cell cytoplasmic S100 extract was established as a 
minimal mechanistic in vitro model to study this process in more detail. Cleavage reactions of a radiolabeled in vitro 
synthesized target RNA by double-stranded siRNA were performed and cleavage products as well as turnover rates were 
measured as a function of Mg
2+ concentration, nucleotide sequence and time. Despite a lot of advances in the understanding 
of RISC activity, different composition sizes and associated factors of this complex have been reported in the literature. The 
above described HeLa cell extract was used to isolate truly active RISCs by purification of complexes via the target mRNA 
component such that involved protein and nucleic acid components can be further characterized. In summary, HeLa cell 
extract was shown to be a valuable tool for kinetic and mechanistic studies of siRNA-mediated RNA interference.  
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Abstract 
MicroRNAs (miRNAs) are small endogenous RNAs, which typically imperfectly base-pair with 3'UTRs and mediate 
translational repression and mRNA degradation.  Dicer, an RNase III generating small RNAs in the miRNA and RNAi 
pathways, is essential for meiotic maturation of mouse oocytes.  We found that 3'UTRs of transcripts up-regulated in 
Dicer1/oocytes are not enriched in miRNA binding sites implicating a weak impact of miRNAs on the maternal 
transcriptome.  Therefore, we tested the ability of endogenous miRNAs to mediate RNA-like cleavage or translational 
repression of reporter mRNAs.  In contrast to somatic cells, endogenous miRNAs in fully-grown GV oocytes poorly 
repressed reporter translation while their RNAi-like activity was much less affected.  In addition, reporter mRNA 
carrying let-7-binding sites failed to localize to P-bodies, cytoplasmic foci containing proteins involved in RNA 
repression and degradation where miRNA-repressed transcripts typically localize. In fact, P-bodies are not found in 
fully-grown mouse oocytes but disappear early during oocyte growth. In fully-grown oocytes, several P-body 
components and other RNA binding proteins including DDX6, CPEB, MSY2, and the exon junction complex form 
transient, subcortical RNA-containing aggregates, which disperse during oocyte maturation, consistent with recruitment 
of maternal mRNAs that occurs during this time. In contrast, levels of P-body component DCP1A are low during 
oocyte growth and DCP1A does not co-localize with DDX6 in the sub-cortical aggregates. The amount of DCP1A 
markedly increases during meiosis, which correlates with the first wave of destabilization of maternal mRNAs. Our data 
suggest that normal miRNA function is down-regulated during oocyte development and this idea is further supported by 
normal meiotic maturation of oocytes lacking Dgcr8, which is required for miRNA but not RNAi pathway. We propose 
that suppression of miRNA function during oocyte growth is an early event in reprogramming gene expression during 
the transition of a differentiated oocyte into pluripotent blastomeres of the embryo. Furthermore, the cortex of growing 
oocytes serves an mRNA storage compartment, which contains a novel type of RNA granule related to P-bodies. 
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Abstract 
Being a member of the Picornavirus family, Coxsackievirus B3 (CVB-3) is one of the major pathogens that may lead to 
dilated cardiomyopathy. It is a small, non-enveloped RNA virus. Because of the plus-stranded RNA genome it is 
qualified for the application of RNA interference. We developed highly efficient small interfering RNAs (siRNAs) 
against the viral 3D RNA dependent RNA polymerase (3D
pol). Hence we were able to inhibit CVB-3 proliferation up to 
90% in a plaque reduction assay. Recent experiments revealed the potential to use siRNAs modified with locked nucleic 
acids (LNA) or unlocked nucleic acids (UNA) to inhibit virus replication. For in vivo applications, vector delivery of 
shRNA expression cassettes was found to be a suitable approach to treat mice with virus-induced myocarditis. An 
AAV-vector expressing two shRNAs against CVB-3 was found to improve the heart parameters in a mouse model for 
an enterovirus myocarditis. Finally, a synergistic and potent antiviral effect in persistently infected human myocardial 
fibroblasts was obtained, when the siRNA was combined with a soluble variant of the coxsackievirus-adenovirus 
receptor, which acts as a virus trap. Taken together, these studies demonstrate that RNA interference is a powerful tool 
to inhibit cardiotropic viruses. 
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Abstract 
Our studies have focused on the application of imaging-capable nanoparticulate agents for the delivery of siRNA to 
target tissues. One example includes magnetic nanoparticles (MN), which have traditionally been utilized as contrast 
agents for magnetic resonance imaging. MN typically consist of a dextran-coated superparamagnetic iron oxide core 
(for magnetic resonance imaging), labeled with Cy5.5 dye (for near-infrared in vivo optical imaging), and conjugated to 
synthetic siRNA molecules targeting model or therapeutic genes. We have explored the potential of these nanoparticles 
as delivery modules for small interfering RNA to tumors and pancreatic islets. Furthermore, we have investigated the 
feasibility of combining the imaging and delivery capabilities of these nanoparticles for the tracking of siRNA 
bioavailability. The versatile functionalization potential of MN has allowed us to control properties of the agents, such 
as uptake mechanism and target organ distribution. The tumoral accumulation of MN-siRNA results in a remarkable 
level of target-gene down-regulation. Repeated treatment with MN-siBIRC5, targeting the tumor-specific anti-apoptotic 
gene, birc5, leads to the induction of apoptosis in the tumors and an overall reduction in tumor growth rate. Another 
application of MN-siRNA extends from the fact that these nanoparticles are also taken up by pancreatic islets following 
in vitro incubation. This uptake can be visualized by magnetic resonance and near-infrared fluorescence optical imaging 
and results in down-regulation of target genes. This approach has relevance in the context of pancreatic islet 
transplantation, which is a promising new treatment of type 1 diabetes. A potential application of this method would 
involve the selective knock-down of genes implicated in islet graft dysfunction, such as pro-apoptotic genes and genes 
involved in immuno-recognition. More recent studies that will be discussed briefly have focused on the delivery of 
knock-down LNA probes targeting specific miRNA pathways. 
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Abstract 
Development of siRNA therapeutics has already demonstrated clinical benefits in more than a dozen human trials.  
Using siRNA cocktail to silence multiple disease genes is truly realizing the advantage of small interfering RNA 
(siRNA)-based drugs.  We have developed a set of siRNA cocktails using our proprietary algorithm and “Tri-
Blocker™” platform, as the active pharmaceutical ingredient (API).  Those siRNA cocktails were further tested and 
validated in the disease relevant animal models using a series of polymer- and liposome-based nanoparticles. The 
therapeutic programs in the late preclinical development stage, STP705 for improving skin scarless wound healing, 
STP702 for treatment of influenza H5N1/H1N1 infections and  STP601 for treatment of ocular neovascularization 
diseases, are all based on the local and topical siRNA delivery using the self-assembled first generation nanoparticles.  
We further developed the second generation nanoparticles with peptide ligands and monoclonal antibodies for targeted 
cancer siRNA therapeutics which were tested in mouse xenograft tumor models.   In addition, we are currently 
developing the third generation siRNA delivery vehicles, using Infrared-activated silica-coated upconversion 
nanoparticle (SC-UPNP) and oral-delivered nano-microspheres (OD-NMS).  When the siRNA cocktail is applied with 
other drug modalities, such as monoclonal antibody, the therapeutic benefit was even further improved.   
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Abstract 
A UsiRNA directed against mRNA for the human survivin gene was formulated into liposomes formed with a novel Di- 
Alkylated Amino Acid (DiLA2) resulting in well encapsulated (>85%) small (100-130 nm) particles. UsiRNAs are 
novel siRNA constructs which incorporate Unlocked Nucleobase Analogs (UNAs) within the oligonucleotide sequence. 
The survivin UsiRNA has been demonstrated to be highly potent, with an in vitro IC50 of 10 to 30 pM, which leads to 
caspase induction and apoptosis in cancer cells. A murine Hep3B-based orthotopic liver cancer model was used to 
assess the in vivo efficacy of the survivin UsiRNA DiLA2 liposomes with systemic administration. Dosing at 2 mg/kg 
(q3d x 6 doses; i.v.) resulted in approximately a 50% knockdown of survivin mRNA and 60% decrease in tumor 
weight. This result compared favorably with Avastin™ (bevacizumab)-treated mice which served as a positive control. 
A similar level of survivin mRNA knockdown was noted in a xenograft model of subcutaneously implanted liver 
tumors and systemic administration. In an orthotopic bladder cancer model, survivin UsiRNA DiLA2 liposomes were 
delivered topically (intravesical dosing) at up to 1.0 mg/kg (q2d x 4 doses). Greater than 90% inhibition of the survivin 
mRNA was observed, and there was a dose-dependent decrease in bioluminescence of up to approximately 90% in 
UsiRNA-treated mice which indicates reduced tumor growth. 5’-RACE analysis confirmed an RNAi-mediated 
mechanism of action for mRNA inhibition in each tumor model. Data for knockdown of multiple targets in tissues of 
normal mice and for a liver target in non-human primates has also been demonstrated with systemic administration of 
DiLA2-based liposomes. Taken together these data demonstrate that DiLA2 liposomes are an effective systemic and 
local delivery system for UsiRNAs, in both cancer and non-cancer indications. 
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Abstract 
MicroRNAs are a recently discovered class of naturally occurring short non-coding RNA molecules that regulate 
eukaryotic gene expression. There is emerging evidence to suggest that microRNAs are involved in the pathogenesis of 
many cancers including B cell lymphoma. There is however little data on the role of microRNAs in T cell lymphomas. 
Therefore we employed microarray analysis to investigate a possible role for microRNAs in the biology of cutaneous T-
cell lymphomas; Sezary syndrome (SzS, n=21), mycosis fungoides (MF, n=26) and cutaneous anaplastic large cell 
lymphoma (cALCL, n=15) and relevant controls (CD4+ cells from healthy subjects (n=6), and skin biopsies from patients 
with inflammatory disorders (n=17). Using unsupervised cluster analysis we observed that the T-cell lymphomas have a 
distinct miRNA profile from their counterpart controls and have distinct profiles between diagnosis. We identified a 
number of miRNAs in common between the T-cell lymphomas and well as those specific for diagnosis. In summary, we 
have identified a number of Sz-associated microRNAs that may play a role in the pathogenesis of these diseases. 
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Abstract 
The sequencing of the human genome revealed that 55% of its nucleotide sequence is composed of repetitive elements 
and that a large fraction of the "non-functional" DNA originated from mobile elements (1). They were considered until 375 
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recently as “selfish” or "Junk DNA" (2). For example, Alu elements comprise about 10% of the nucleotides of the 
human genome (1), with over one million inserted copies. There is evidence showing that the presence of repetitive 
elements had a great influence on the human genome and it has been shown that Alu repeats are mediators of recurrent 
chromosomal aberrations in tumors as in the case of the chromosomal translocation of intronic Alu elements (3). 
Recently, it was reported that some mammalian miRNAs are derived from genomic repeats and some of them show 
perfect complementarity with the MIR/LINE-2 class of repetitive elements, which are present within a large number of 
human mRNAs and EST transcripts (4). It was hypothesized that Alu elements within the 3’-UTRs are targeted 
specifically by certain miRNAs (5) and it has been proposed that a dual relationship exists between miRNAs and their 
Alu targets that may have evolved in the same time window. One hypothesis for this dual relationship is that these 
miRNAs could protect against excessively high rates of duplicative transposition, which would destroy the genome (6). 
Here we present the computational prediction of human miRNA/transposon interactions. We performed the analysis by 
using a combined approach based on thermodynamics and empirical constraints and found significant matches between 
miRNAs and human repetitive elements such as LINE, SINE, DNA transposon and ERV1. For example, over 30 
miRNAs potentially target the L180_5 element (LINE1 family; 1883 nucleotides) and over 20 miRNAs are predicted to 
target the RICKSHA element (Non-autonomous DNA transposon fossil; 2030 nucleotides). We considered perfect seed 
complementarity only (7-mers or higher), with no G:U wobbles. The obtained results suggest a potential role of 
miRNAs in the regulation of repetitive elements and in particular transposons.  
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